Is there an oligometastatic state in pancreatic cancer?: Practical clinical considerations raise the question

Marta Scorsetti; Tiziana Comito; Davide Franceschini; Ciro Franzese; Maria Giuseppina Prete; Antonio D'Alessio; Silvia Bozzarelli; Lorenza Rimassa; Armando Santoro

doi:10.1259/bjr.20190627

Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question

Marta Scorsetti, Tiziana Comito, Davide Franceschini, Ciro Franzese, Maria Giuseppina Prete, Antonio D'Alessio, Silvia Bozzarelli, Lorenza Rimassa, Armando Santoro

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVES: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer.

METHODS: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS).

RESULTS: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8).

CONCLUSIONS: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results.

ADVANCES IN KNOWLEDGE: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.

Original language	English
Pages (from-to)	20190627
Journal	The British journal of radiology
Volume	93
Issue number	1106
DOIs	https://doi.org/10.1259/bjr.20190627
Publication status	Published - Feb 1 2020

Keywords

Adenocarcinoma/mortality
Aged
Aged, 80 and over
Disease Progression
Disease-Free Survival
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neoplasm Metastasis
Pancreatic Neoplasms/mortality
Positron-Emission Tomography
Radiosurgery/methods
Retrospective Studies

Access to Document

10.1259/bjr.20190627

Fingerprint Dive into the research topics of 'Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question'. Together they form a unique fingerprint.

Cite this

Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. / Scorsetti, Marta; Comito, Tiziana; Franceschini, Davide; Franzese, Ciro; Prete, Maria Giuseppina; D'Alessio, Antonio; Bozzarelli, Silvia ; Rimassa, Lorenza ; Santoro, Armando.

In: The British journal of radiology, Vol. 93, No. 1106, 01.02.2020, p. 20190627.

Research output: Contribution to journal › Article › peer-review

Scorsetti, Marta ; Comito, Tiziana ; Franceschini, Davide ; Franzese, Ciro ; Prete, Maria Giuseppina ; D'Alessio, Antonio ; Bozzarelli, Silvia ; Rimassa, Lorenza ; Santoro, Armando. / Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. In: The British journal of radiology. 2020 ; Vol. 93, No. 1106. pp. 20190627.

@article{eb3dd39ca8df4d2f84b1fdf838f86ed5,

title = "Is there an oligometastatic state in pancreatic cancer?: Practical clinical considerations raise the question",

abstract = "OBJECTIVES: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer.METHODS: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS).RESULTS: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8).CONCLUSIONS: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results.ADVANCES IN KNOWLEDGE: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.",

keywords = "Adenocarcinoma/mortality, Aged, Aged, 80 and over, Disease Progression, Disease-Free Survival, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms/mortality, Positron-Emission Tomography, Radiosurgery/methods, Retrospective Studies",

author = "Marta Scorsetti and Tiziana Comito and Davide Franceschini and Ciro Franzese and Prete, {Maria Giuseppina} and Antonio D'Alessio and Silvia Bozzarelli and Lorenza Rimassa and Armando Santoro",

year = "2020",

month = feb,

day = "1",

doi = "10.1259/bjr.20190627",

language = "English",

volume = "93",

pages = "20190627",

journal = "British Journal of Radiology",

issn = "0007-1285",

publisher = "British Institute of Radiology",

number = "1106",

}

TY - JOUR

T1 - Is there an oligometastatic state in pancreatic cancer?

T2 - Practical clinical considerations raise the question

AU - Scorsetti, Marta

AU - Comito, Tiziana

AU - Franceschini, Davide

AU - Franzese, Ciro

AU - Prete, Maria Giuseppina

AU - D'Alessio, Antonio

AU - Bozzarelli, Silvia

AU - Rimassa, Lorenza

AU - Santoro, Armando

PY - 2020/2/1

Y1 - 2020/2/1

N2 - OBJECTIVES: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer.METHODS: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS).RESULTS: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8).CONCLUSIONS: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results.ADVANCES IN KNOWLEDGE: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.

AB - OBJECTIVES: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer.METHODS: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS).RESULTS: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8).CONCLUSIONS: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results.ADVANCES IN KNOWLEDGE: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.

KW - Adenocarcinoma/mortality

KW - Aged

KW - Aged, 80 and over

KW - Disease Progression

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Pancreatic Neoplasms/mortality

KW - Positron-Emission Tomography

KW - Radiosurgery/methods

KW - Retrospective Studies

U2 - 10.1259/bjr.20190627

DO - 10.1259/bjr.20190627

M3 - Article

C2 - 31825664

VL - 93

SP - 20190627

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1106

ER -